Risk of atypical femoral fracture during and after bisphosphonate use: Full report of a nationwide study

Acta Orthopaedica

Volumn 86, Issue 1, 2015, Pages 100-107

  Schilcher, Jörg ^a   Koeppen, Veronika ^a   Aspenberg, Per ^a   Michaëlsson, Karl ^b  

^a LINKÖPING UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; RISEDRONIC ACID; BONE DENSITY CONSERVATION AGENT; ETIDRONIC ACID;

ADULT; AGED; ARTICLE; COMORBIDITY; CONTROLLED STUDY; FEMALE; FEMUR SHAFT FRACTURE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; RISK ASSESSMENT; RISK REDUCTION; STRESS FRACTURE; ANALOGS AND DERIVATIVES; CASE CONTROL STUDY; COHORT ANALYSIS; FEMORAL FRACTURES; MIDDLE AGED; OSTEOPOROTIC FRACTURES; RADIOGRAPHY; RETROSPECTIVE STUDY; RISK FACTOR; SEX DIFFERENCE; SWEDEN; TIME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; CASE-CONTROL STUDIES; COHORT STUDIES; DIPHOSPHONATES; ETIDRONIC ACID; FEMALE; FEMORAL FRACTURES; HUMANS; MALE; MIDDLE AGED; OSTEOPOROTIC FRACTURES; RETROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; SWEDEN; TIME FACTORS;

EID: 84921823001     PISSN: 17453674     EISSN: 17453682     Source Type: Journal    
DOI: 10.3109/17453674.2015.1004149     Document Type: Article

References (44)

1. Bergstrom M F, Byberg L, Melhus H, Michaelsson K, Gedeborg R. Extent and consequences of misclassified injury diagnoses in a national hospital discharge registry. Inj Prev 2011; 17 (2): 108-13.
2. Black D M, Kelly M P, Genant H K, Palermo L, Eastell R, Bucci-Rechtweg C, et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 2010; 362 (19): 1761-71.
3. Black D M, Bauer D C, Schwartz A V, Cummings S R, Rosen C J. Continuing bisphosphonate treatment for osteoporosis - for whom and for how long? N Engl J Med 2012; 366 (22): 2051-3.
4. Charlson M E, Pompei P, Ales K L, MacKenzie C R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40 (5): 373-83.
5. Cummings S R, Black D M, Thompson D E, Applegate W B, Barrett-Connor E, Musliner T A, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998; 280 (24): 2077-82.
6. Curtis J R, Westfall A O, Cheng H, Lyles K, Saag K G, Delzell E. Benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101,038 new bisphosphonate users. J Bone Miner Res 2008; 23 (9): 1435-41.
7. Dell R M, Adams A L, Greene D F, Funahashi T T, Silverman S L, Eisemon E O, et al. Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res 2012; 27 (12): 2544-50.
8. Eastell R, Walsh J S, Watts N B, Siris E. Bisphosphonates for postmenopausal osteoporosis. Bone 2011; 49 (1): 82-8.
9. Ebetino F H, Hogan A M, Sun S, Tsoumpra M K, Duan X, Triffitt J T, et al. The relationship between the chemistry and biological activity of the bisphosphonates. Bone 2011; 49 (1): 20-33.
10. Ettinger B, Burr D B, Ritchie R O. Proposed pathogenesis for atypical femoral fractures: lessons from materials research. Bone 2013; 55 (2): 495-500.
11. Feldstein A C, Weycker D, Nichols G A, Oster G, Rosales G, Boardman D L, et al. Effectiveness of bisphosphonate therapy in a community setting. Bone 2009; 44 (1): 153-9.
12. Feldstein A C, Black D, Perrin N, Rosales A G, Friess D, Boardman D, et al. Incidence and demography of femur fractures with and without atypical features. J Bone Miner Res 2012; 27 (5): 977-86.
13. Gedmintas L, Solomon D H, Kim S C. Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis. J Bone Miner Res 2013; 28 (8): 1729-37.
14. Girgis C M, Sher D, Seibel M J. Atypical femoral fractures and bisphosphonate use. N Engl J Med 2010; 362 (19): 1848-9.
15. Giusti A, Hamdy N A, Papapoulos S E. Atypical fractures of the femur and bisphosphonate therapy: A systematic review of case/case series studies. Bone 2010; 47 (2): 169-80.
16. Greenland S R, Rothman K. J. Introduction to Stratified Analysis In: Modern Epidemiology, Third Edition. (Ed. Rothman KJG, S. Lash, T. L.). Lippincott Williams and Wilkins: Philadelphia; 2008.
17. Inderjeeth C A, Foo A C, Lai M M, Glendenning P. Efficacy and safety of pharmacological agents in managing osteoporosis in the old old: review of the evidence. Bone 2009; 44 (5): 744-51.
18. Ing-Lorenzini K, Desmeules J, Plachta O, Suva D, Dayer P, Peter R. Lowenergy femoral fractures associated with the long-term use of bisphosphonates. Drug Saf 2009; 32 (9): 775-85.
19. Kharazmi M, Michaelsson K, Hallberg P. Prodromal symptoms in patients with bisphosphonate-associated atypical fractures of the femur. J Bone Miner Metab 2014 Oct 16. [Epub ahead of print].
20. Ludvigsson J F, Andersson E, Ekbom A, Feychting M, Kim J L, Reuterwall C, et al. External review and validation of the Swedish national inpatient register. BMC public health 2011; 11: 450.
21. Meier R P, Perneger T V, Stern R, Rizzoli R, Peter R E. Increasing occurrence of atypical femoral fractures associated with bisphosphonate use. Arch Intern Med 2012; 172 (12): 930-6.
22. Norman T L, Wang Z. Microdamage of human cortical bone: incidence and morphology in long bones. Bone 1997; 20 (4): 375-9.
23. Odvina C V, Zerwekh J E, Rao D S, Maalouf N, Gottschalk F A, Pak C Y. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005; 90 (3): 1294-301.
24. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi J, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005; 43 (11): 1130-9.
25. Rose G, Hamilton P J. A randomised controlled trial of the effect on middleaged men of advice to stop smoking. J Epidemiol Community Health 1978; 32 (4): 275-81.
26. Rosen C J, Hochberg M C, Bonnick S L, McClung M, Miller P, Broy S, et al. Treatment with once-weekly alendronate 70 mg compared with onceweekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res 2005; 20 (1): 141-51.
27. Rydholm A. Highly different risk estimates for atypical femoral fracture with use of bisphosphonates - debate must be allowed! Acta Orthop 2012; 83 (4): 319-20.
28. Schilcher J. Epidemiology, radiology and histology of atypical femoral fractures. Acta Orthop Suppl 2013; 84 (352): 1-26.
29. Schilcher J, Aspenberg P. Incidence of stress fractures of the femoral shaft in women treated with bisphosphonate. Acta Orthop 2009; 80 (4): 413-5.
30. Schilcher J, Michaelsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 2011; 364 (18): 1728-37.
31. Schilcher J, Koeppen V, Ranstam J, Skripitz R, Michaelsson K, Aspenberg P. Atypical femoral fractures are a separate entity, characterized by highly specific radiographic features. A comparison of 59 cases and 218 controls. Bone 2013; 52 (1): 389-92.
32. Schilcher J, Koeppen V, Aspenberg P, Michaelsson K. Risk of atypical femoral fracture during and after bisphosphonate use. N Engl J Med 2014a; 371 (10): 974-6.
33. Schilcher J, Sandberg O, Isaksson H, Aspenberg P. Histology of 8 atypical femoral fractures. Acta Orthop 2014b: 1-7.
34. Seeman E. Bone quality: the material and structural basis of bone strength. J Bone Miner Metab 2008; 26 (1): 1-8.
35. Shane E, Burr D, Abrahamsen B, Adler R A, Brown T D, Cheung A M, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the american society for bone and mineral research. J Bone Miner Res 2014; 29 (1): 1-23.
36. Silverman S L, Schousboe J T, Gold D T. Oral bisphosphonate compliance and persistence: a matter of choice? Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2011; 22 (1): 21-6.
37. Sim Ie W, Ebeling P R. Treatment of osteoporosis in men with bisphosphonates: rationale and latest evidence. Therapeutic advances in musculoskeletal disease 2013; 5 (5): 259-67.
38. Talley C, Kushner H I, Sterk C E. Lung cancer, chronic disease epidemiology, and medicine, 1948-1964. Journal of the history of medicine and allied sciences 2004; 59 (3): 329-74.
39. U.S. Department of Health and Human Services. The Health Consequences of Smoking: A Report of the Surgeon General. The Health Consequences of Smoking: A Report of the Surgeon General.: Atlanta, GA: U.S.; 2004.
40. Valimaki M J, Karkkainen M, Lamberg-Allardt C, Laitinen K, Alhava E, Heikkinen J, et al. Exercise, smoking, and calcium intake during adolescence and early adulthood as determinants of peak bone mass. Cardiovascular Risk in Young Finns Study Group. BMJ (Clinical research ed) 1994; 309 (6949): 230-5.
41. Wells G, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, et al. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008a; (1): CD004523.
42. Wells G A, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, et al. Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008b; (1): CD003376.
43. Wells G A, Cranney A, Peterson J, Boucher M, Shea B, Welch V, et al. Alendronate for preventing fractures caused by osteoporosis in postmenopausal women. Cochrane Database Syst Rev 2008c; (1): CD001155.
44. Whitaker M, Guo J, Kehoe T, Benson G. Bisphosphonates for osteoporosis - where do we go from here? N Engl J Med 2012; 366 (22): 2048-51.